Quarterly ResultMay 12, 2026, 04:07 PM
LB Pharmaceuticals Initiates Two Late-Stage Trials; Cash $365.6M
AI Summary
LB Pharmaceuticals announced its first quarter 2026 financial results and provided a corporate update. The company initiated the pivotal Phase 3 NOVA-2 trial for schizophrenia and the Phase 2 ILLUMINATE-1 trial for bipolar depression, with plans for a Phase 2 trial in adjunctive MDD. Cash, cash equivalents, and marketable securities stood at $365.6 million as of March 31, 2026, expected to fund operations into Q2 2029. The net loss for the quarter was $19.1 million, reflecting increased R&D expenses for advancing its clinical pipeline, supported by a recent $100 million private placement.
Key Highlights
- Initiated pivotal Phase 3 NOVA-2 trial for schizophrenia in March 2026, with topline data expected H2 2027.
- Initiated Phase 2 ILLUMINATE-1 trial for bipolar depression in January 2026, with topline data expected Q1 2028.
- Cash, cash equivalents, and marketable securities were $365.6 million as of March 31, 2026.
- Cash expected to fund operations into Q2 2029, through multiple clinical milestones.
- Net loss for Q1 2026 was $19.1 million, compared to $5.3 million in Q1 2025.
- Research & Development expenses rose to $14.6 million in Q1 2026 from $3.4 million in Q1 2025.
- Completed a $100 million private placement in February 2026, yielding $93.8 million net proceeds.